Skip to main content

2022 IKCS: North America Main banner

Tweets by 2022 IKCS: North America

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Martin H. Voss, MD

Memorial Sloan Kettering Cancer Center

Poster(s):

36: Impact of subsequent therapies in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab or sunitinib in the CLEAR study